Explore the words cloud of the PET-AlphaSy project. It provides you a very rough idea of what is the project "PET-AlphaSy" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||4˙100˙370 €|
|EC max contribution||4˙100˙370 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2018-09-01 to 2022-08-31|
Take a look of project's partnership.
|1||KOBENHAVNS UNIVERSITET||DK (KOBENHAVN)||coordinator||892˙566.00|
|2||STICHTING VUMC||NL (AMSTERDAM)||participant||796˙859.00|
|3||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||758˙365.00|
|4||UPPSALA UNIVERSITET||SE (UPPSALA)||participant||563˙965.00|
|5||REGION HOVEDSTADEN||DK (HILLEROD)||participant||297˙522.00|
|6||BIOARCTIC AB||SE (STOCKHOLM)||participant||281˙982.00|
|8||JOHANNES GUTENBERG-UNIVERSITAT MAINZ||DE (MAINZ)||participant||252˙788.00|
|9||Eckert & Ziegler Eurotope GmbH||DE (Berlin)||partner||0.00|
|10||H. LUNDBECK AS||DK (VALBY)||partner||0.00|
|11||ION BEAM APPLICATIONS SA||BE (OTTIGNIES LOUVAIN LA NEUVE)||partner||0.00|
|12||NOVO NORDISK A/S||DK (BAGSVAERD)||partner||0.00|
|13||PMOD TECHNOLOGIES GMBH||CH (ADLISWIL)||partner||0.00|
|14||POSITRONPHARMA SA||CL (SANTIAGO)||partner||0.00|
|15||TAGWORKS PHARMACEUTICALS BV||NL (Eindhoven)||partner||0.00|
|16||UNIVERSITE DE LIEGE||BE (LIEGE)||partner||0.00|
Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified. This leads to a critical loss of time, making the healthcare system ineffective and expensive. In respect to drug development, a high failure rate is apparent at all stages of development and ways to reduce this have high priority for the pharmaceutical industry. To this end, drug development and medicinal treatment need to be more personalized and molecular imaging techniques, in particular Positron Emission Tomography (PET) imaging, can be used to achieve this by 1) evaluating the effectiveness of new treatments emerging from the pharmaceutical industry, 2) improving the ability to diagnose diseases, and 3) aid tailoring the treatment based on individual patient pathology. A limiting factor to develop new effective PET imaging probes is the insufficient number of radiopharmaceutical scientists presently available. Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to address this problem and train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine. Furthermore, this consortium will train entrepreneurial skills and facilitate start up new enterprises in the current favorable radioisotope market situation.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PET-ALPHASY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PET-ALPHASY" are provided by the European Opendata Portal: CORDIS opendata.